Introduction
Despite considerable progress in the treatment of acute and chronic coronary artery disease (CAD) during the past years, CAD still remains the largest single killing disease in the USA 1 and Europe. 2 Approximately one-third of coronary attacks results in death in the USA 1 and similar numbers apply to Europe. These numbers stress the need for early detection of disease. The presence of perfusion deficits has been shown to be one of the strongest predictors of cardiac death and non-fatal myocardial infarction (MI) in large studies, 3 and ischaemia imaging takes a central position in guidelines for the work-up of patients with known or suspected CAD. 4, 5 Scintigraphy is widely used for ischaemia detection and it has been shown to be cost-effective. 6 In recent years, several studies documented a high diagnostic performance of perfusion-cardiac magnetic resonance (CMR) vs. conventional X-ray coronary angiography (CXA) 7 -13 and showed its prognostic value. 14 This evidence triggered an increasing utilization of perfusion-CMR in clinical practice and its impact on clinical patient management was recently demonstrated. 15 The current MR-IMPACT II trial was designed to compare the diagnostic performance of CMR vs. single-photon emission computed tomography (SPECT) for the detection of perfusion deficits in CAD (defined as ≥75% area reduction in coronary vessels in CXA) in a large international multicentre, multivendor design. We enrolled 533 patients in 33 study centres across Europe and the USA. Patients were characterized for the presence of CAD by CXA (reference standard), perfusion-CMR, and SPECT. Cardiac magnetic resonance and SPECT were each analysed by three blinded readers in core laboratories for the presence or absence of perfusion abnormalities.
Methods

Study design and patient population
This Phase III clinical trial was conducted at 33 centres in Europe and the USA (see Supplementary material online for a list of participating sites). Eligible patients were those scheduled for a conventional CXA and/or a SPECT examination for clinical reasons. Before study entry, all patients had to agree to undergo all three imaging studies. Table 1 shows the inclusion/exclusion criteria. The study was conducted according to the Declaration of Helsinki, the principles of Good Clinical Practice, and was approved by the Health Authorities and the local Ethics Committee of each participating institution. All patients gave written informed consent before study participation.
Efficacy measures
Diagnostic performances of CMR and SPECT were assessed with two efficacy measures: it was tested for non-inferiority of both sensitivity and specificity for CMR vs. SPECT for the detection of CAD (¼primary study endpoint). Thus, a binary approach was used, i.e. reading was assessed at one threshold. As secondary endpoints, sensitivity, specificity, and negative and positive predictive values for the CMR examination were calculated as well as the safety profile of CMR.
Definition of coronary artery disease: reference standard
The study was designed to determine the sensitivity and specificity of CMR and SPECT to detect perfusion deficits in patients with suspected or known CAD. It was not the aim to discriminate perfusion deficits into ischaemia vs. scar tissue, since CMR is known for its excellent power to differentiate viable from scar tissue, 16 which could have introduced a bias in favour of CMR. For the definition of CAD, i.e. to define patients with perfusion deficits, two criteria were used: first, the presence of a ≥50% diameter stenosis (i.e. ≥75% area stenosis) measured in two orthogonal planes as was used in previous studies 7 -9,17 present in ≥1 coronary artery of ≥2 mm diameter using a core laboratory (Cleveland Clinic Foundation, Cleveland, OH, USA). Thus, a ≥50% diameter reduction had to be present in both orthogonal projections to define CAD. This criterion accounted for 94.6% of all patients in this study. Secondly, the history of a previous MI was considered. This way, patients after MI (and thus with perfusion deficits in scar tissue on resting perfusion images) do fulfil the criteria for the presence of perfusion deficits in CAD [e.g. patients with successful percutaneous coronary interventions (PCI)/stenting in the setting of acute MI and consequently non-stenosed coronary arteries]. This second criterion to define CAD (¼history of previous MI without significant stenosis on CXA) was relevant for 5.4% of all patients included. Conversely, patients with a history of successful PCI/stenting (with a residual area stenosis ≤75% in the actual CXA) and without a history of MI do not fulfil the definition of CAD (and are assumed to yield normal perfusion studies at stress and at rest). Vessels of ,2 mm diameter were not considered for definition of CAD, since such small vessels are rarely treated (e.g. no stents available for ,2 mm vessels).
Cardiac magnetic resonance examination In 1.5 T scanners of various vendors, a breath-hold MR first-pass perfusion examination was performed to follow a bolus of 0.075 mmol/kg Gd-DTPA-BMA (Omniscan, GE Healthcare, USA) injected into a peripheral vein with power injectors at 5 mL/s (followed by a 25 mL saline flush) after 3 min of adenosine infusion (0.14 mg/min/kg i.v. short-axis slices were acquired every heart beat at one-fourth, half, and three-fourth of the left ventricular (LV) long axis (non-slice selective 908-preparation, fast gradient-echo acquisition with an echo-planar component where available; spatial resolution: 2-3 mm × 2-3 mm, slice thickness 8 -10 mm). An example is given in Figure 1 . At the same locations, at 10 and 25 min after the stress imaging, a rest perfusion imaging at the same CM dose and a late enhancement study (with the inversion time nulling normal myocardium at the cumulated CM dose of 0.15 mmol/kg) were performed, respectively. Cardiac magnetic resonance data were analysed visually by three blinded readers in an independent core laboratory (Independent Review Center, GE Healthcare, former Nycomed Amersham Imaging, Princeton, NJ, USA). The three readers were blinded with respect to any clinical information of the patients or results of the other examinations. For the single threshold analysis, a binary assessment of the CMR studies was performed as either showing a perfusion abnormality in any of the 16 segments of the heart at rest and/or at stress (abnormal study) or not (normal study). Perfusion abnormalities were defined as myocardium being black or dark grey at the peak bolus. Borderline normal perfusion (myocardium being light grey) was classified together with normal perfusion (myocardium being bright). Additional criteria indicative for true hypoperfusion vs. artefacts were subendocardial signal reduction persisting longer than the CM first-pass through the LV cavity, signal reduction in several slices, and neighbouring regions. 9 From this binary judgement, sensitivity and specificity scores were defined as the number of readers with correct diagnosis (true-positive and truenegative, respectively) divided by the number of all readers (¼3) yielding values between 0 and 1 (e.g. all three readers correct for true-positive: sensitivity score Sens MR ¼ 1; e.g. one reader of three correct for truenegative: specificity score Spec MR ¼ 0.33). By using scores of sensitivity and specificity, the sensitivity and specificity results of the three readers were combined into one value/patient, which facilitated subsequent non-inferiority testing.
Single-photon emission computed tomography examination
Stress and rest SPECT examinations were performed according to generally accepted guidelines 18 additional patients for rest studies only (6.9 and 1.7%, respectively). Algorithms for attenuation correction or resolution recovery were not applied as these were not available or not identical over all sites. Single-photon emission computed tomography data were analysed visually by three blinded readers using a core laboratory (Beacon Bioscience, Inc., Doylestown, PA, USA). The three readers were blinded with respect to any clinical information of the patients or results of the other examinations. Each reader was presented with 10 -12 short-axis as well as 6 -9 vertical and horizontal long-axis Figure 1 An example of a 67-year-old patient is shown with angina CCS II. The perfusion-cardiac magnetic resonance study during hyperaemia (at 0.075 mmol/kg Gd-DTPA-BMA) demonstrates a perfusion deficit in the subendocardium of the anterolateral wall (B and C; arrows). In the apical slice, almost the entire subendocardium is hypoperfused during hyperaemia (C, arrows). Another minor perfusion deficit is detected in the inferior wall of the basal and mid-ventricular slices (A and B, arrowheads). In the basal slice in (A), the inferior wall of the right ventricle also shows hypoperfusion in comparison with the right ventricular free wall. Single-photon emission computed tomography in this patient was positive with a predominant perfusion abnormality in the anteroseptal wall (F-K ). Quantitative X-ray coronary angiography (QCA) demonstrated a severe stenosis in the left anterior descending coronary artery of 82% (LAD; D, arrow). The right coronary artery (RCA) shows two mild stenoses of 64 and 59% diameter reduction (E, arrows).
images for both stress and rest conditions. Gated-SPECT data were also presented to the readers, if they had been acquired. For the primary endpoint, a binary assessment of the SPECT studies was performed as either being normal or not according to generally accepted guidelines. 18 Specifically, SPECT studies were categorized as either showing a perfusion abnormality in any segment of a 17-segment model at rest and/or at stress (¼abnormal study) or not (¼normal study). Also, patients with a transient ischaemic LV dilation were categorized as abnormal. From this binary judgement, sensitivity and specificity scores (Sens SPECT and Spec SPECT ) were calculated as described for the CMR data.
Safety parameters
In all patients dosed with the CM, the following was recorded: adverse events, findings of physical examinations (1 -24 h before CM administration and 24 h thereafter), vital signs (systolic/diastolic blood pressure, heart rate, and respiratory rate at 10 and 6 min before CM administration, during adenosine infusion, and at the end of the CMR study, as well as 15, 60 -90 min, and 24 h thereafter), laboratory parameters (serum biochemistry, hematology, and coagulation parameters within 36 h before and 24 h after first CM administration), and 12-lead electrocardiographic (ECG) tracings (immediately before the CMR study, and 60-90 min and 24 h thereafter). Core laboratories for blood sample analyses and 12-lead ECG analyses were CRL-Medinet Europe, Breda, The Netherlands, and Biomedical Systems (BMS) Europe, Brussels, Belgium, respectively.
Statistical analysis
Sample size calculation for non-inferiority for sensitivity and specificity
To meet the efficacy measure for non-inferiority of sensitivity, this criterion had to be met in each of two parallel substudies. Accordingly, for the primary endpoint of sensitivity, 139 subjects were calculated to yield a 90% power to show non-inferiority of CMR vs. SPECT at an equivalence limit difference of 20.1 with a target significance level of 0.025 (nQuery Advisor 5.0) using an SD of the difference of 0.36 for CMR (derived from the Phase II clinical study: MR-IMPACT 1 ). Hence, non-inferiority is inferred if the lower bound of the confidence interval (CI) falls within the equivalence margin of 20.10 (¼10% non-inferiority margin: H 0 : Sens MR -Sens SPECT , 20.1). The criterion of non-inferiority of specificity had to be met in the entire study (¼substudies 1 and 2). Accordingly, for the primary endpoint assessment of specificity, the two identical Phase III substudies combined had to achieve a 90% power to show non-inferiority of CMR vs. SPECT at an equivalence limit difference of 20.1 with a target significance level of 0.025 (nQuery 5.0) expecting 30 -40% of negative subjects from each of the two Phase III substudies. The substudies 1 and 2 included 238 and 227 patients, respectively (efficacy population ¼ dosed patients with complete data sets).
For the primary endpoint of non-inferiority of CMR vs. SPECT, non-inferiority was inferred, if the lower bounds of the CIs for the sensitivity and specificity scores fall within the equivalence margin of 20.10 (¼10% non-inferiority margin: H 0 : Sens MR -Sens SPECT , 20.1). In the case of superiority, i.e. if the lower bounds of the CIs for sensitivity or specificity fall above 0, superiority is reported. 19 All tests were two-sided and a P-value of ,0.05 was considered statistically significant. Statistical analyses were performed using SAS w software (Version 8.2).
Results
Patient characteristics
From the 533 patients enrolled, 515 entered the safety analysis (¼patients received MR CM; Figure 2 ). Of the 465 patients with data of all three modalities complete (¼efficacy population; Figure 2 Flow chart demonstrating the number of eligible patients and drop-outs. CMR, cardiac magnetic resonance; CM, contrast medium (Gd-DTPA-BMA); CXA, coronary X-ray angiography; Pats, patients; SPECT, single-photon emission computed tomography.
P ¼ 0.74). When applying a single, i.e. binary threshold, to the CMR and SPECT images, the sensitivity scores were 0.67 and 0.59, respectively (P ¼ 0.024, paired t-test), with the lower confidence level for the difference of +0.02, indicating superiority of CMR over SPECT for sensitivity (efficacy population: n ¼ 465). The specificity score for CMR and SPECT was 0.61 and 0.72, respectively (P ¼ 0.038, paired t-test) with a lower confidence level for the difference of 20.17, indicating inferiority of CMR vs. SPECT for specificity. For CMR and SPECT, sensitivities (mean + SD of all readers) were 75 + 7 and 59 + 10%, respectively (P ¼ 0.03) and specificities were 59 + 8 and 72 + 14%, respectively (P ¼ 0.03). Positive and negative predictive values and accuracies (mean + SD of all readers) for CMR were 70 + 5, 65 + 5, and 68 + 5%, respectively, and for SPECT 73 + 8, 60 + 3, and 65 + 3%, respectively (no significant differences).
Safety profile of the cardiac magnetic resonance examinations
In all 515 patients, who received the MR CM, no severe adverse events and no deaths occurred. Table 3 shows the moderate and mild adverse events. There were no trends for clinically significant changes in vital signs or ECG changes following MR CM administration.
Discussion
The main results of the trial can be summarized as follows: (i) the primary endpoint of non-inferiority of CMR vs. SPECT for the detection of CAD was met for sensitivity, but not for specificity.
(ii) No severe adverse effects occurred in the 515 patients who received the MR CM during pharmacological stress CMR.
Perfusion-cardiac magnetic resonance and single-photon emission computed tomography comparison
This large multicentre perfusion trial demonstrates a higher sensitivity of perfusion-CMR to detect perfusion deficits in CAD than a Safety: all six serious adverse events were classified by the treating physician as not drug-related. Prolonged hospital stays were due to treatment by PCI/CABG of severe CAD during the same hospitalization.
SPECT. Thus, this trial confirms trends and results of earlier multicentre 9 and single-centre studies, 11 respectively, and objectivates an important feature of CMR, i.e. to correct for both cardiac motion and respiratory motion during the few seconds of CM firstpass during hyperaemia. This approach preserves the nominally high spatial resolution of perfusion-CMR and thereby allows detecting small even subendocardial perfusion deficits. However, at a single threshold reading of the CMR and SPECT data, this level of sensitivity was associated with a specificity for CMR lower than that for SPECT. One may also speculate that this relatively low specificity of perfusion-CMR is related to the fact that perfusion was compared with the macroscopic coronary artery anatomy, which does not assess, for example, collateral flow on the microvascular level.
The MR-IMPACT II results are in accord with a previous smaller multicentre single-vendor perfusion-CMR study, 8 which yielded a sensitivity and specificity of 93% (95% CI of 77 -99%) and 75% (95% CI of 48 -92%), respectively, vs. MR-IMPACT II with 75% (69 -80%) and 59% (52 -65%), respectively. The 95% CIs for sensitivity are overlapping between the current MR-IMPACT II and the previous MR-IMPACT I (69 -80 vs. 69 -93%, respectively); however, there is a trend towards slightly lower sensitivity in the MR-IMPACT II vs. MR-IMPACT I with 85 vs. 75%, respectively. Also specificity showed a trend towards better performance in MR-IMPACT I with 67% vs. MR-IMPACT II with 59%, while the 95% CIs are overlapping (35-89 vs. 52 -65%, respectively). This might be related to the larger number of participating sites in MR-IMPACT II, by which less experienced centres could have contributed to the database. Also, in MR-IMPACT II, a slightly lower CM dose was used than the most effective dose in MR-IMPACT I. The current MR-IMPACT II results are also in agreement with the large CE-MARC single-centre CMR study performed in 628 patients and published recently. 20 In this CE-MARC trial, a sensitivity of 80% on the receiver-operator characteristic (ROC) curve corresponds to a specificity of 70%. 20 The SPECT results of the MR-IMPACT II with a sensitivity and specificity of 59 and 72%, respectively, are also in close match which those of MR-IMPACT I. In MR-IMPACT I, a sensitivity of 60% corresponded to a specificity of 75% on the ROC curve, which is also in line with the single-centre CE-MARC trial, where a SPECT sensitivity of 60% corresponded to a specificity of 70% on the ROC curve. 20 Nevertheless, one might have expected somewhat better results for either, SPECT and/or CMR for the detection of CAD in the MR-IMPACT II. The aim of this large MR-IMPACT II was to assess test performances in a realistic clinical environment across a substantial number of countries and not to repeat the results of a few leading high-performance centres. To this end, it was crucial to accept in the protocol a certain range of imaging parameters as long as they were in agreement with key features of the technique (such as spatial and temporal resolution for CMR and concordance with established guidelines for SPECT). Of note, gated SPECT was performed in 54% of the patients and attenuation correction algorithms were not applied (due to a lack of standardized criteria). These circumstances should be taken into account when considering the overall SPECT performance.
In addition, when assessing the current performances of both CMR and SPECT, it should be kept in mind that these results were obtained in a fully blinded fashion and, thus, are expected to potentially underestimate test performance in the clinical setting where imaging information is generally interpreted in the context of additional patient information.
Safety of perfusion-cardiac magnetic resonance examinations
The results of this MR-IMPACT II confirm the high safety profile reported in earlier CMR perfusion trials 8 -10,12 as no severe adverse events occurred among the 515 patients in MR-IMPACT II. This finding is in good agreement with the safety profile observed in the European CMR registry with mild adverse reactions reported in 0.1% of 7285 stress CMR studies and where no severe reactions occurred. 21 Unlike SPECT, CMR does not expose patients to ionizing radiation. 22 
Limitations of the study
The area stenosis on CXA was used as the reference standard for the definition of CAD. Coronary artery disease was also present by definition in a small portion of 5.4% of the study patients with a history of infarction where the infarct-related artery was successfully treated by PCI, and thus, the treated vessel was no longer stenosed. Accordingly, this definition of CAD is primarily dependent on coronary anatomy and it is well known that the presence of perfusion deficits is not only dependent on stenoses of epicardial coronary arteries, but also on collateral flow and microcirculatory alterations. Nevertheless, this definition was deemed best as it is relatively easy to measure, is frequently used in such comparative studies, and often sets the basis for patient management in clinical routine. For future comparative studies, however, invasive perfusion assessment by fractional flow reserve measurements would be desirable. Importantly, an optimal patient management should always consider the patient prognosis. Perfusion techniques are very powerful prognostic tools, and in this regard, evidence is particularly well established for SPECT. The current study results apply for pharmacological stress testing only. In this trial, patients with decompensated heart failure, after bypass surgery, and with relevant arrhythmias were excluded, and thus, the findings of this study cannot be applied to these patient groups. The frequency of CAD in this study was 48.8%, and therefore, the study results are applicable to patient populations with an intermediate CAD prevalence, but the trial results cannot be extrapolated to other populations with lower disease prevalence, e.g. to asymptomatic screening populations.
For this evaluation, 26 (5.6% of 465) CMR and 17 (3.7% of 465, P ¼ 0.21 vs. CMR) SPECT studies were deemed non-evaluable by the MR and SPECT readers, respectively, which limit the applicability of the results to patients with evaluable studies.
Conclusions
This large international, multicentre, multivendor, prospective trial performed at 33 centres demonstrates a high performance of perfusion-CMR to detect CAD. Sensitivity of perfusion-CMR was superior to perfusion SPECT, while specificity of perfusion-CMR was inferior in comparison to SPECT. In selected patients (no severe arrhythmias), CMR is a safe approach and an alternative to SPECT to detect perfusion abnormalities in CAD.
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